Result:Poor· Market: Down
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 0.00 | ||
| Total Income | 0.09 | 21.4% | 91.1% |
| Expenditure | 0.02 | 69.5% | 79.2% |
| PBT | 0.07 | 70.7% | 92.6% |
| Net Profit | -0.02 | 103.1% | 102.9% |
| OPM | — | ||
| NPM | -21.44% | 121.44pp | 88.14pp |
| EPS | 0.22 | 50.0% | 54.2% |
Pharma micro-cap with zero core revenue in both periods, swinging to a net loss from a prior-year profit driven entirely by other income — a clear deterioration, not a turnaround.
Informational and educational content only. Not investment advice.